Loading
Prostate Cancer Treatment and Research / Diabetes Treatment and Management / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Frontiers in Urology · August 7, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study found that GLP-1RA use was associated with lower all-cause mortality compared to DPP-4i (HR 0.60) and SGLT2i (HR 0.76) in men with prostate cancer on ADT and type 2 diabetes, with additional benefits on kidney and thrombotic events versus DPP-4i. The findings are limited by observational design and acknowledged low event power, and prospective confirmation is recommended by the authors.
Retrospective cohort study with propensity score matching. Adults with type 2 diabetes and prostate cancer undergoing androgen-deprivation therapy enrolled from TriNetX network. Intervention: Glucagon-like peptide-1 receptor agonist (GLP-1RA). Compared with: Dipeptidyl peptidase-4 inhibitor (DPP-4i) or sodium–glucose cotransporter-2 inhibitor (SGLT2i). n = 659. TriNetX network (not further specified).
GLP-1RA versus DPP-4i: all-cause mortality HR 0.60 (95% CI 0.46–0.79), MAKEs HR 0.63 (95% CI 0.48–0.81), thrombotic events HR 0.53 (95% CI 0.32–0.89), MACEs HR 0.87 (95% CI 0.63–1.12) not significant GLP-1RA versus SGLT2i: all-cause mortality HR 0.76 (95% CI 0.59–0.99), no significant differences in MACEs, MAKEs, or thrombotic events Post-matching cohorts: 659 per group for GLP-1RA versus DPP-4i comparison; 1,009 per group for GLP-1RA versus SGLT2i comparison
GLP-1RA versus DPP-4i: all-cause mortality HR 0.60 (95% CI 0.46–0.79), MAKEs HR 0.63 (95% CI 0.48–0.81), thrombotic events HR 0.53 (95% CI 0.32–0.89), MACEs HR 0.87 (95% CI 0.63–1.12) not significant GLP-1RA versus SGLT2i: all-cause mortality HR 0.76 (95% CI 0.59–0.99), no significant differences in MACEs, MAKEs, or thrombotic events
GLP-1RA may be a favorable option for men with prostate cancer on ADT with comorbid diabetes, particularly regarding mortality reduction versus DPP-4i and SGLT2i. However, this observational finding requires prospective validation before practice change; unmeasured confounding and selection bias cannot be excluded.
Retrospective cohort study with propensity matching showing mortality and renal benefits of GLP-1RA versus comparators in a specific high-risk population, but limited by observational design, potential unmeasured confounding, and modest event numbers acknowledged by authors.
As stated by the source record.
Quoted from the source exactly as published.
GLP-1RA may be a favorable option for men with prostate cancer on ADT with comorbid diabetes, particularly regarding mortality reduction versus DPP-4i and SGLT2i. However, this observational finding requires prospective validation before practice change; unmeasured confounding and selection bias cannot be excluded.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT) frequently develop cardiometabolic complications, particularly those with type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in diabetic populations, but comparative evidence with other glucose-lowering therapies in men receiving ADT remains limited. We conducted a retrospective cohort study using the TriNetX network. Adults with T2D and PCa undergoing ADT who received GLP-1RA, dipeptidyl peptidase-4 inhibitors (DPP-4is), or sodium–glucose cotransporter-2 inhibitors (SGLT2is) between January 2005 and December 2025 were included. Propensity score matching generated balanced cohorts for two comparisons: GLP-1RA versus DPP-4i and GLP-1RA versus SGLT2i. The primary outcome was all-cause mortality; secondary outcomes were major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs), and thrombotic events. After matching, 659 patients per group were included in the GLP-1RA versus DPP-4i comparison and 1,009 per group in the GLP-1RA versus SGLT2i comparison. Compared with DPP-4i, GLP-1RA use was associated with lower all-cause mortality (HR, 0.60; 95% CI, 0.46–0.79), MAKEs (HR, 0.63; 95% CI, 0.48–0.81), and thrombotic events (HR, 0.53; 95% CI, 0.32–0.89), whereas MACEs were similar (HR, 0.87; 95% CI, 0.63–1.12). Compared with SGLT2i, GLP-1RA use was associated with lower all-cause mortality (HR, 0.76; 95% CI, 0.59–0.99), whereas no significant differences were observed for MACEs, MAKEs, or thrombotic events. These neutral findings should be interpreted cautiously because the limited number of events may have reduced statistical power to detect modest between-group differences. In conclusion, among men with PCa receiving ADT and comorbid T2D, GLP-1RA use was associated with lower all-cause mortality than both DPP-4i and SGLT2i, with additional reductions in kidney and thrombotic events versus DPP-4i. GLP-1RAs may represent a favorable therapeutic option in this metabolically and vascularly vulnerable population. Prospective studies are warranted to confirm these associations and clarify the underlying mechanisms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.